Pasteur Korea, Sanofi team up to develop new Hepatitis B drugs

By Park Sae-jin Posted : April 26, 2013, 10:00 Updated : April 26, 2013, 10:00
The Institute Pasteur Korea (IPK) said on Feb. 5 that it has signed a contract with Sanofi S.A., a pharmaceutical company, to develop new drugs for chronic Hepatitis B infections.

Although there are medicines and vaccines for the Hepatitis B virus, about 5 percent of the world's population suffer from the virus, IPK officials said.

Those infected with the virus are at a high risk of developing liver cirrhosis and liver cancer, they said.
기사 이미지 확대 보기
닫기